Assessment of the impact of glioma diagnostic reclassification following the new 2016 WHO classification on a series of cases

• Published in: Neurocirugia (Asturias, Spain) Vol. 30; no. 1; pp. 19 - 27
• Main Authors: Valera-Melé, Marc, Mateo Sierra, Olga, Sola Vendrell, Emma, Guzmán de Villoria L, Juan Adán, Carvajal Díaz, Lorena, Gil de Sagredo Del Corral, Óscar Lucas, García Leal, Roberto
• Format: Journal Article
• Language: English; Spanish
• Published: Spain 01-01-2019
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Astrocytoma - classification; Astrocytoma - diagnosis; Astrocytoma - pathology; Child; Child, Preschool; Female; Glioma - classification; Glioma - diagnosis; Glioma - pathology; Humans; Infant; Male; Middle Aged; Molecular Diagnostic Techniques; Oligodendroglioma - classification; Oligodendroglioma - diagnosis; Oligodendroglioma - pathology; Retrospective Studies; World Health Organization; Young Adult; Codeleción 1p19q; Molecular genetics; WHO 2016 classification; Genética molecular; Astrocitoma; IDH; Clasificación OMS 2016; Astrocytoma; Codeletion 1p19q; Oligodendroglioma
• ISSN: 2340-6305; 2529-8496
• DOI: 10.1016/j.neucir.2018.09.002

The aim of this project is to assess diagnostic reclassification based on molecular data over morphology in a series of glial tumours since the introduction of the 2016 WHO classification of brain tumours.
Retrospective review of glial tumours (oligodendrogliomas and astrocytomas) treated in our centre between January 2012 and June 2016 in which a review of diagnosis was performed when molecular studies were added. Statistical analysis included evaluation of variables of epidemiology, morphology and molecular data (mainly IDH mutation and 1p19q codeletion), diagnostic changes after new classification was considered, and clinical impact in cases of diagnostic reclassification.
From a total of 147 glial tumours reviewed in our centre, molecular diagnosis was obtained in 74 cases (50.3%). Initial diagnosis changed in 23 cases (31%), and 20 (87%) of them had a prior histological diagnosis of oligodendroglioma (69.6% grade ii and 17.4% grade iii). Only 3 of these 23 cases diagnosis changed from astrocytoma to oligodendroglioma. Among reclassified tumours, there was a common molecular pattern, as findings showed mutant IDH in 16 cases (69.6%) and no codeletion in 20 cases (87%). According to the cell of origin, of the whole group of 27 oligodendrogliomas in our series (reclassified and non-reclassifed), 20 cases (74%) became astrocytomas, despite typical oligodendroglial morphology, due to absence of 1p19q codeletion. There was a trend for diagnosis reclassification in younger patients (<40 years), P=.065, mainly in those with a prior diagnosis of oligodendroglioma, with no statistical differences based on gender or clinical data. Besides, reclassification was more common among tumours with mutant IDH (69.6%), P=.003, than those with wild type IDH. In terms of survival, despite receiving different treatments, no significant changes were detected between reclassified and non-reclassified tumours after a mean follow-up of 16 months, partly related to lower grade of these lesions.
Within the spectrum of the glial tumours treated in our institution, this new classification including molecular genetics over morphological data has provided marked diagnostic changes. These changes appear mainly in tumours previously diagnosed as oligodendrogliomas and in younger patients, with molecular patterns of mutant IDH and 1p19q codeletion. Although diagnosis reclassification may affect clinic, prognosis or therapeutic management of these tumours, deeper and prospective studies on these specific aspects are needed.